Axogen (AXGN) Left Russell Indices, Is The Upside Already Priced In?
Axogen (AXGN) has been removed from several Russell indices, causing a 4.7% share price decline, although it still boasts significant year-to-date and 1-year returns. Conflicting valuation narratives exist, with one model suggesting it's 13.3% undervalued at $50.78 due to strong growth in peripheral nerve repair, while another DCF model calculates a fair value of $34.47, indicating the current price of $44.02 is expensive. The article advises investors to assess the numbers themselves.
Axogen (AXGN) Left Russell Indices, Is The Upside Already Priced In?
Axogen (AXGN) has been removed from several Russell indices, yet its stock shows strong momentum with significant year-to-date and one-year returns. While some models suggest it's undervalued by 13.3% due to potential growth in peripheral nerve repair, an alternative DCF model indicates the current share price might be expensive. Investors are advised to consider various financial indicators and risks before making investment decisions.
Will Axogen’s (AXGN) Russell Index Removal Reshape Its Liquidity Profile and Risk‑Reward Narrative?
Axogen Inc. (AXGN) was recently removed from several Russell indexes, which could impact its trading liquidity and passive ownership. Despite this, the company's investment narrative remains focused on its nerve repair portfolio and achieving profitability, with 2026 revenue guidance of at least $270 million. Investors should consider the company's reliance on its Avance product and potential risks related to regulation, reimbursement, or competition.
Axogen stock hits 52-week high at 46.05 USD By Investing.com
Axogen Inc. (AXGN) stock reached a new 52-week high of $46.05, representing a 317.97% increase over the past year and a market capitalization of $2.43 billion. This surge is supported by strong revenue growth and a high gross profit margin, reflecting positive investor confidence, though InvestingPro analysis suggests the stock may be overvalued. The company recently reported strong Q1 2026 earnings with revenue beating expectations, leading analysts to raise price targets, despite a slight miss on adjusted net income.
Axogen stock hits 52-week high at 46.05 USD
Axogen Inc. (AXGN) stock reached a new 52-week high of $46.05, representing a significant 317.97% increase over the past year and pushing its market capitalization to $2.43 billion. This surge is driven by strong revenue growth of 22% and a 75% gross profit margin. Despite its strong performance, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value estimate.
Axogen, Inc.(NasdaqCM: AXGN) dropped from Russell 3000E Index
Axogen, Inc. (NasdaqCM:AXGN) has been dropped from the Russell 3000E Index, the Russell Microcap Index, and the Russell 3000E Growth Benchmark. This news, published on June 29, 2026, reflects changes in the composition of these major stock market indices. The company's stock experienced a 4.25% change on the day this announcement was made.
Will Axogen’s (AXGN) Russell Index Removal Reshape Its Liquidity Profile and Risk‑Reward Narrative?
Axogen (AXGN) was recently removed from several Russell indexes, which could impact its liquidity and passive fund ownership. Despite this, the company's investment narrative still hinges on the wider adoption of its nerve repair portfolio and achieving profitability, with a 2026 revenue growth guidance of at least 20%. The article emphasizes the importance of execution and warns investors about the concentrated dependence on its Avance product.
Will Axogen’s (AXGN) Russell Index Removal Reshape Its Liquidity Profile and Risk‑Reward Narrative?
Axogen, Inc.'s removal from several Russell indexes, including the Microcap and 3000E indexes, is expected to impact its trading liquidity and passive fund ownership. While this development doesn't alter current growth catalysts or risks related to its biologic nerve repair portfolio and profitability, it will reshape the investment narrative and longer-term risk-reward profile, prompting investors to focus on execution, regulatory progress for Avance, and cost control. The company's 2026 guidance projects at least 20% revenue growth to US$270 million and gross margins of 74-76%.
Price to earnings forward of Axogen, Inc. – NASDAQ:AXGN
This article provides financial information for Axogen, Inc. (NASDAQ: AXGN), specifically its forward price-to-earnings ratio. It is presented in a data-driven format from TradingView, focusing on key financial metrics for investors. The content is sparse, indicating the user would need to navigate the TradingView platform for detailed figures.
Axogen (AXGN) director Paul Thomas receives $235K RSU grant vesting in 2027
Axogen, Inc. director Paul Thomas has been granted 5,579 restricted stock units (RSUs) valued at $235,000 as equity compensation for his Board service. These RSUs will vest on June 24, 2027, which marks the one-year anniversary of the grant date. Following this transaction, Thomas's direct holdings from this grant amount to 5,579 units.
Axogen (AXGN) director Alan Levine granted 4,392 RSUs valued at $185K
Axogen, Inc. director Alan M. Levine was granted 4,392 restricted stock units (RSUs) as an annual equity award for his service on the Board. The grant is valued at $185,000 and the RSUs are set to vest on June 24, 2027, which is the one-year anniversary of the grant date. Following this transaction, Levine directly holds 4,392 RSUs linked to Axogen common stock, with each RSU representing a contingent right to receive one share.
Form 4 Axogen Inc For: 26 June By Investing.com
The article "Form 4 Axogen Inc For: 26 June" from Investing.com reports on a Form 4 filing for Axogen Inc (AXGN) dated June 26, 2026. This type of filing is typically used to disclose changes in beneficial ownership of securities by company insiders. The article notes a +4.25% change for AXGN.
Axogen (AXGN) director receives 4,392 RSUs in $185,000 equity grant
Axogen, Inc. director Joseph A. Tyndall received an equity grant of 4,392 restricted stock units (RSUs) as compensation for his board service. This grant is valued at $185,000 and will vest on June 24, 2027, which is the one-year anniversary of the grant date. Following this award, Tyndall directly holds 4,392 RSUs, indicating a routine compensation acquisition rather than an open-market purchase.
Form 4 Axogen Inc For: 26 June By Investing.com
This article from Investing.com reports that a Form 4 filing for Axogen Inc. was submitted on June 26. The brief piece indicates this filing is related to stock market activity for the company. No further details about the specific transactions are provided.
Axogen (AXGN) director receives 4,392 restricted stock units in annual equity grant
Axogen, Inc. director William P. Burke received an annual equity grant of 4,392 restricted stock units (RSUs) as compensation for his service on the Board of Directors. These RSUs, valued at $185,000 as of the grant date, represent a contingent right to receive one share of Axogen common stock per unit. The units are scheduled to vest on June 24, 2027, and following this grant, Burke directly holds 4,392 RSUs.
Axogen (AXGN) director John Johnson receives 4,392 RSUs valued at $185,000
Axogen, Inc. director John Johnson received an annual equity grant of 4,392 restricted stock units (RSUs) as compensation for his service on the Board of Directors. This award, valued at $185,000, is scheduled to vest on June 24, 2027, provided service conditions are met. Each RSU represents a contingent right to receive one share of Axogen common stock, making this a compensation grant rather than an open-market purchase.
Axogen (AXGN) director receives $185K equity grant of 4,392 RSUs vesting 2027
Axogen, Inc. director Kathy Johnson Weiler was granted 4,392 restricted stock units (RSUs) as part of her annual equity compensation, valued at $185,000. These RSUs represent a contingent right to receive one share of Axogen common stock per unit and are set to vest on June 24, 2027. This transaction was reported in a Form 4 filing, indicating an acquisition of shares with no monetary transaction involved for the director.
Axogen (AXGN) director Wendell McBride awarded 4,392 RSUs valued at $185,000
Axogen (AXGN) director Wendell Amy McBride was granted 4,392 Restricted Stock Units (RSUs) as an annual equity award for her service on the Board of Directors. The grant, valued at $185,000, represents a contingent right to receive one share of common stock per unit, vesting on June 24, 2027. This transaction is compensation and not an open-market share purchase.
Q1 2025 AxoGen Inc Earnings Call Transcript
This article provides the Q1 2025 earnings call transcript for AxoGen Inc (AXGN), detailing positive outcomes such as a 17.4% revenue increase and progress on a biologics license application (BLA) for advanced nerve graft. However, it also highlights negative aspects including a decrease in gross margin and delays in sales team expansion. The call outlines financial results, corporate highlights, and future guidance from the CEO and CFO.
AXGN Forecast — Price Target — Prediction for 2027
This article provides a forecast for Axogen, Inc. (AXGN) stock, including price targets and analyst ratings for 2027. It details financial information, historical price performance, and upcoming earnings dates, alongside frequently asked questions about the company's stock, market capitalization, and volatility.
Price to earnings forward of Axogen, Inc. – FWB:LT3
This article focuses on the "Price to earnings forward" metric for Axogen, Inc. (FWB:LT3). The content provided is minimal, only stating the period, value, and change for this financial metric, alongside a note that it was "Made by humans."
Axogen, Inc. Actuals & Estimates (NASDAQ:AXGN)
This article provides an in-depth financial overview of Axogen, Inc. (NASDAQ:AXGN), including its current stock price, historical performance, analyst forecasts, and various financial metrics. It details income statement, balance sheet, and cash flow data, alongside frequently asked questions about the company's stock, earnings, and market capitalization. The piece also mentions that Axogen will release its next earnings report on August 12, 2026.
Enterprise value to revenue forward of Axogen, Inc. – NASDAQ:AXGN
This article focuses on the enterprise value to revenue forward metric for Axogen, Inc. (NASDAQ: AXGN). It appears to be a financial data point provided by TradingView, indicating a key valuation ratio for the company. The content itself is an extremely sparse snippet, likely a title or entry point to a more detailed financial analysis.
Axogen (AXGN) Stock After 314% One-Year Surge Is The Rally Losing Steam?
Axogen (AXGN) has seen a significant 314% surge over the past year, leading investors to question if its current price of US$42.52 is sustainable. Despite this strong performance, Simply Wall St's valuation checks, including Discounted Cash Flow and Price/Sales analysis, suggest that the stock is currently overvalued. The article details these valuation methods and encourages investors to explore company narratives for a more comprehensive understanding.
Price to book forward of Axogen, Inc. – NASDAQ:AXGN
This page from TradingView provides financial information for Axogen, Inc. under the NASDAQ:AXGN ticker. It specifically highlights the "Price to book forward" metric for the company. The content also lists various features and services offered by TradingView.
Responsive Playbooks and the AXGN Inflection
Axogen Inc. (NASDAQ: AXGN) is showing a near-term neutral sentiment amidst mid and long-term strength, with a mid-channel oscillation pattern identified. The report highlights an exceptional 39.3:1 risk-reward short setup targeting an 11.7% downside versus 0.3% risk. Three distinct AI-generated trading strategies are provided: a long position strategy, a momentum breakout strategy, and a risk hedging short strategy, along with multi-timeframe signal analysis.
Form 4 Axogen Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Axogen Inc (AXGN) dated June 23, 2026. Form 4s disclose changes in beneficial ownership of company stock by insiders. The article provides the ticker symbol AXGN and notes a 4.63% increase for the stock, placing it within a broader financial news context rather than detailing the specifics of the Form 4.
Axogen (AXGN) director gains 18,867 common shares from RSU vesting
Axogen, Inc. director Thomas Paul acquired 18,867 shares of common stock on June 19, 2026, through the vesting of restricted stock units (RSUs). This transaction, an annual equity grant for board service valued at $200,000 at the grant date, increased his direct holdings to 32,395 shares of Axogen common stock. The event was not an open-market purchase but a routine conversion of RSUs.
Axogen shareholders elect board members and approve auditor at annual meeting
Axogen, Inc. (NASDAQ:AXGN) shareholders held their 2026 annual meeting, electing eight directors to the board, ratifying Deloitte & Touche LLP as the independent auditor, and approving executive compensation. The medical technology company's stock is trading near its 52-week high, with shares up 359% over the past year, though current valuation metrics suggest it may be overvalued. This comes after AxoGen reported strong Q1 2026 earnings with a 27% revenue increase.
Form 4 Axogen Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Axogen Inc. dated June 23. Form 4 filings are legally required documents filed with the SEC by company insiders, indicating a change in their ownership of company stock. The brief article also includes various market data and other news.
Form 4 Axogen Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Axogen Inc. dated June 23. It provides the financial details and context surrounding this regulatory filing.
Axogen (AXGN) director gains 14,150 shares from RSU vesting
Axogen, Inc. director Joseph A. Tyndall reported the vesting of 14,150 restricted stock units on June 19, 2026, which converted into 14,150 shares of common stock. This equity grant for board service was valued at $150,000 on the grant date. The transaction was a compensation-related equity award vesting, not an open-market purchase or sale.
Axogen (NASDAQ: AXGN) director receives 14,150 shares from $150K RSU grant
Axogen Inc. (NASDAQ: AXGN) director Kathy Johnson Weiler acquired 14,150 shares of common stock on June 19, 2026, due to the vesting of restricted stock units (RSUs). These RSUs, originally valued at $150,000 as an annual equity compensation for her Board service, converted into common shares at $0.00 per share. Following this transaction, Weiler directly holds 14,150 shares of Axogen common stock, with all related RSUs fully settled.
Form 4 Axogen Inc For: 23 June By Investing.com
This article reports on a Form 4 filing for Axogen Inc, specifically for activity on June 23rd. Form 4 filings are legally required documents submitted to the SEC by company insiders, detailing their transactions in the company's securities. The content indicates that the filing is relevant to the stock market.
Axogen (AXGN) director gains 14,150 common shares from RSU vesting
Axogen, Inc. director John Johnson acquired 14,150 shares of common stock on June 19, 2026, through the vesting and conversion of restricted stock units. These RSUs were an annual equity grant for his board service, valued at $150,000 at the grant date and vested on their one-year anniversary. Following the transaction, Johnson holds 14,150 common shares and zero restricted stock units.
Axogen (AXGN) director Burke receives 14,150 shares from vested RSU grant
Axogen, Inc. director William P. Burke received 14,150 shares of common stock from a vested restricted stock unit (RSU) grant on June 19, 2026. This was a routine annual equity grant for his service on the Board of Directors, valued at $150,000 on the grant date. Following this transaction, Burke directly holds 14,250 shares of Axogen common stock, with no open-market purchases or sales reported.
AxoGen Inc (AXGN) Institutional Confidence
AxoGen Inc (AXGN) has received an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This score reflects a high level of institutional confidence despite a slight quarter-over-quarter decrease in institutional shareholding proportion to 91.60%. Ron Baron is highlighted as the largest institutional shareholder, holding 1.21% of outstanding shares.
AxoGen Inc (AXGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
AxoGen Inc (AXGN) currently holds an earnings forecast score of 8.40, ranking 37th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $36.00 for AXGN, with forecasts ranging from $27.00 to $40.00. The consensus among 10 analysts is a "Buy" rating for the stock.
AxoGen Inc (AXGN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of AxoGen Inc (AXGN), noting its current valuation score is 8.62, ranking 76th in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -70.53, and mentions that P/B, P/S, and P/CF data have not been disclosed yet. The information was updated on June 18, 2026.
AxoGen Inc (AXGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of AxoGen Inc (AXGN), detailing its price momentum score of 9.60, ranking 3rd in its industry. It identifies current support at $40.00 and resistance at $47.76, suggesting suitability for range-bound swing trading. The analysis also includes a summary of various technical indicators, showing a "Buy" signal based on moving averages.
AxoGen Inc (AXGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a limited overview of AxoGen Inc's revenue breakdown, focusing on regional contributions. For FY2023 and FY2022, data regarding business segments and profit contributions have not yet been disclosed by the company. The only specific financial data provided is that the United States contributed $159.01 million in revenue.
AxoGen Inc (AXGN) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of AxoGen Inc (AXGN) focusing on its dividend history and stock splits. It states that AxoGen Inc has not distributed any dividends over the past five years and has no recorded stock split data. The current stock price and market capitalization are also presented.
AXGN Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for AxoGen Inc (AXGN), indicating a strong buy consensus based on various technical indicators. It details moving averages, momentum indicators like RSI and MACD, and key support and resistance levels for the stock. Ultimately, the analysis suggests a bullish outlook for AXGN, trading above its key moving averages.
Understanding the Setup: (AXGN) and Scalable Risk
This article analyzes Axogen Inc. (AXGN) with a current neutral sentiment in the near and mid-term, but a positive bias for the long-term. AI models have generated three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis highlights an exceptional 43.0:1 risk-reward setup, targeting a 12.1% gain versus 0.3% risk.
Assessing Axogen (AXGN) Valuation After A Strong 90 Day Share Price Gain
Axogen (AXGN) has seen a 35.1% share price gain over the past three months, despite reporting net losses. While a popular narrative suggests the stock is 18.4% undervalued with a fair value of $50.78 based on future growth, its current Price/Sales ratio of 9.3x is significantly higher than industry averages, indicating potential valuation risk. Investors are advised to consider both the potential rewards from accelerating revenue and the risks, such as reliance on its Avance Nerve Graft and regulatory setbacks, before making investment decisions.
Market Sentiment Around Loss-Making Axogen, Inc. (NASDAQ:AXGN)
This article analyzes market sentiment around Axogen, Inc. (NASDAQ:AXGN), a company that is currently unprofitable. It aims to determine whether investors are anticipating future growth or are concerned about its current financial state.
AxoGen (NASDAQ:AXGN) Cut to "Hold" at Wall Street Zen
Wall Street Zen downgraded AxoGen (NASDAQ:AXGN) from a "buy" to a "hold" rating, though most other analysts maintain a "buy" rating with a consensus target price of $46.50. The company reported mixed Q1 earnings, missing EPS expectations but exceeding revenue forecasts, while also showing negative net margin and return on equity. Insider selling and significant institutional ownership were also noted in the report.
AXGN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of AxoGen Inc (AXGN), detailing its revenue composition, profitability margins, and a comparison with competitors. AXGN exhibits a strong gross margin of 75.16% but reports negative operating and net margins, as well as a negative Return on Equity. The company is benchmarked against peers like XRAY and ESTA, highlighting its competitive gross margin.
Market Sentiment Around Loss-Making Axogen, Inc. (NASDAQ:AXGN)
NULL
The Technical Signals Behind (AXGN) That Institutions Follow
This article analyzes Axogen Inc. (NASDAQ: AXGN) using AI models to identify technical signals and institutional trading strategies. It highlights a weak near- and mid-term sentiment but a strong long-term outlook, with specific entry, target, and stop-loss zones for position trading, momentum breakouts, and risk hedging. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.
